Cardiovascular Risk Reduction in Type 2 Diabetes: The Nurse Practitioner's Role in Optimizing Outcomes

This educational activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

This activity is jointly provided by Global Education Group and Physicians’ Education Resource®, LLC.
On Demand Webinar


Lucia M. Novak, MSN, ANP-BC, BC-ADM,
Riverdale, Maryland
Adjunct Assistant Professor, Graduate School of Nursing
Uniformed Services University of the Health Sciences
Bethesda, Maryland

Activity Overview

The challenges of Type 2 diabetes (T2DM) management and treatment are enormous, with a host of macrovascular and microvascular complications.  Therapy goals aim to avoid acute osmotic symptoms of hyperglycemia, avoid instability in blood glucose over time, and prevent or delay the development of diabetes complications, without adversely affecting quality of life.  In this activity, expert faculty will review clinical trial data for new treatments and their different mechanisms of action that target plasma glucose as well as cardiometabolic risk factors.  Strategies for integrating these new therapies into clinical practice will be presented to achieve glycemic control and reduce overall cardiometabolic risk in an individualized treatment plan.

Educational Objectives

  1. DESCRIBE how to integrate current guideline recommendations concerning diabetes therapies into clinical practice
  2. IDENTIFY patient comorbidities that would impact drug selection
  3. EXPLAIN how to develop individualized approaches for effectively improving outcomes that take into consideration patient characteristics, disease factors, and patient priorities when individualizing goals and therapies for patients with T2DM
  4. SUMMARIZEclinical trial data supporting the use of antidiabetic therapy in reducing macrovascular risk factors associated with T2DM, including hypertension and heart failure
  5. EXPLAIN how a multidisciplinary approach to patient care can positively impact patient outcomes in those suffering from DM
Targeted Audience: Primary Care NPs, Specialty NP’s with an interest in T2DM, Endocrinology NP’s, and Cardiology NPs
Length of Webinar: 1 hour
Release Date: December 27, 2017
Expiration Date: December 27, 2018
Fee: Free

Nurse Practitioner Continuing Education

AANP Provider Logo - Updated 01-22-2013This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through joint providership of Global Education Group and Physicians’ Education Resource, LLC. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education.  Provider number: 1561024. This activity is approved for 1.0 contact hour, which includes 0 hour(s) of pharmacology.

Activity ID #2543E
This activity was planned in accordance with AANP CE Standards and Policies.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Instructions to Receive Credit

To receive credit, participants must complete the online pretest, view the activity in its entirety, and complete the online posttest and activity evaluation form. After completing the online assessment tests, and completing the activity evaluation form, participants may request credit. All participants must request credit by December 21, 2018; CE credit will not be issued after this date.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC
Advisory Board – Sanofi US
Consultant – CeQur, Intarcia, Sanofi-Aventis Group
Speakers Bureau - Astra Zeneca, Janssen, Novo Nordisk
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Kristen Delisi, NP Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
David Heckard Nothing to disclose
Gloria Lauria Nothing to disclose
Katie Pierson Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Physicians’ Education Resource, LLC (PER®) do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements


Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*
MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh
For questions about this Internet CE activity, please contact:
Privacy Policy and Terms of Use Information:

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By